# Mosanna Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mosanna-therapeutics

- Industry: Biotechnology
- Headquarters: Redwood City, US
- Website: www.mosanna.com
- Total disclosed funding: $80M
- Latest round: Series A (Jun 9, 2025)
- Investors on record: 8

## About

Founded in 2022 and based in California, US, Mosanna Therapeutics AG is a biotech company that operates as a manufacturer of therapeutic devices used for treating patients experiencing metabolic obstructive sleep apnea. In June 2025, Mosanna Therapeutics raised USD 80 million in series A funding co-led by new investors Pivotal Life Sciences and EQT Life Sciences, with participation from other new investors Forbion, Broadview Ventures, and Norwest Venture Partners. Returning investors Forty51 Ventures, High-Tech Gruenderfonds, and Supermoon Capital also participated in the round. The company offers a precision medicine approach that improves patient outcomes and quality of life in diseases with high unmet needs. The firm is developing MOS-118 (formerly known as AVE0118), an advanced small molecule for metabolic obstructive sleep apnea (MOSA), a condition associated with adverse cardiovascular events and poor health outcomes. The company will use the June 2025 funding for the advancement of MOS118 through its Phase 2 clinical trials.

## Funding rounds

- Series A, Jun 9, 2025, $80M — Norwest Venture Partners, EQT Life Sciences, Forbion, Broadview Ventures, High-Tech Gruenderfonds, Pivotal Life Sciences, Supermoon Capital, Forty51 Ventures
- Seed, Apr 11, 2023 — High-Tech Gruenderfonds, Supermoon Capital, Forty51 Ventures
- Seed, Jul 13, 2022 — Forty51 Ventures

## Investors

- Forty51 Ventures (https://capitalatlas.ai/funds/forty51-ventures) — Seed, Series A
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed, Series A
- Supermoon Capital (https://capitalatlas.ai/funds/supermoon-capital) — Seed, Series A
- Norwest Venture Partners (https://capitalatlas.ai/funds/norwest-venture-partners) — Series A
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- Broadview Ventures (https://capitalatlas.ai/funds/broadview-ventures) — Series A
- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Series A